ReviewClinical pharmacokinetics2022
Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin.
Review in Clinical pharmacokinetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06266494 (Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis), which is not on this map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Dalbavancin for infective endocarditis: A systematic review of effectiveness, safety, and dosing.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Pooled it
- Updated antimicrobial dosing recommendations for obese patients.Antimicrobial agents and chemotherapy · 2024Pooled it
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- Real-World Effectiveness of Dalbavancin in Osteomyelitis Without Implantable Devices: A Retrospective Monocentric Study.Antibiotics (Basel, Switzerland) · 2026Article
- Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.The Journal of antimicrobial chemotherapy · 2026Article
- Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
- Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections.Antimicrobial agents and chemotherapy · 2025Observational
- Article
- Mannose Derivatives as Anti-Infective Agents.International journal of molecular sciences · 2025Review
- Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections.Antimicrobial agents and chemotherapy · 2025Article
- Glycopeptides: Insights Towards Resistance, Clinical Pharmacokinetics and Pharmacodynamics.Indian journal of microbiology · 2025Article
- Article
- Multidose Dalbavancin Population Pharmacokinetic Analysis for Prolonged Target Attainment in Patients Requiring Long-Term Treatment.Antibiotics (Basel, Switzerland) · 2025Article
- Bridging the Gap: A Systematic Review with Expert Opinion on the Use of Dalbavancin for In-Label and Off-Label Indications in Pediatric Patients.Antibiotics (Basel, Switzerland) · 2025Review
- Dalbavancin Use in Bone and Joint Infections.Arthroplasty today · 2024Article
- Population Pharmacokinetics and Pharmacodynamics of Dalbavancin and C-Reactive Protein in Patients with Staphylococcal Osteoarticular Infections.Clinical pharmacokinetics · 2024Article
- Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Review
- [Outpatient parenteral anti-infective therapy (OPAT)].Innere Medizin (Heidelberg, Germany) · 2024Article
- Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular/periprosthetic joint infections.Antimicrobial agents and chemotherapy · 2024Article
- Rapid and Effective Treatment of Peritonitis in Peritoneal Dialysis Patients with Intravenous Dalbavancin.The American journal of case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dalbavancin is a synthetic lipoglycopeptide that exerts its antimicrobial activity through two distinct modes of action, inhibition of cell wall synthesis and an anchoring mechanism. Compared with previous glycopeptide antibiotics, dalbavancin demonstrates improved antibacterial potency against Gram-positive organisms and a long half-life of approximately 1 week, which is longer in tissues (e.g., skin, bone) than plasma. These factors facilitated the development of single-dose or once-weekly dosing regimens to treat acute bacterial skin and skin structure infections (ABSSSI). Dalbavancin exhibits dose-proportional pharmacokinetics and is highly protein bound (93%). Despite being highly protein bound, it has a steady-state volume of distribution >10 L and distributes widely into the skin, bone, peritoneal space, and epithelial lining fluid, but not cerebrospinal fluid. Dalbavancin elimination occurs via a combination of renal (approximately 45%) and non-renal clearance, with dose adjustments recommended only in patients with a creatinine clearance <30 mL/min not receiving any form of dialysis. The established pharmacokinetic/pharmacodynamic index associated with bacterial kill is free area under the concentration-time curve over the minimum inhibitory concentration (fAUC/MIC), with a goal 24-h fAUC/MIC of at least 27.1 for Staphylococcus aureus infections. Recent data suggest usefulness in the treatment of infections beyond ABSSSI, with convenient dosing and redosing strategies for complicated infections requiring extended treatment durations. Additional studies are needed to confirm these preliminary findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.